Bernstein Lifts PT on UnitedHealth Group (UNH) to $444 From $440

Core Viewpoint - UnitedHealth Group Incorporated (NYSE:UNH) is currently viewed as a strong investment opportunity, with multiple analysts raising price targets and maintaining positive ratings on the stock, anticipating a turnaround in the coming years [1][2][3]. Group 1: Analyst Ratings and Price Targets - Bernstein raised the price target for UnitedHealth Group to $444 from $440 and maintained an Outperform rating, expecting sector improvements in 2026 [1]. - Evercore ISI initiated coverage with an Outperform rating and a $400 price target, expressing optimism for a turnaround in 2026 [2]. - Barclays increased its price target to $391 from $386 while maintaining an Overweight rating, highlighting potential benefits for managed care stocks in 2026 [3]. - RBC Capital reiterated a Buy rating with a price target of $408, following UnitedHealth's announcement regarding Optum Rx's modernization efforts [3]. Group 2: Business Developments - UnitedHealth Group is focusing on enhancing community pharmacy support through Optum Rx, with 100% of community and independent pharmacies in its network adopting a new reimbursement model [4]. - The initiative involves over 17,000 community pharmacies partnering with Optum Rx to implement cost-based contracts [4]. - UnitedHealth Group operates through various segments, including OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare, providing healthcare coverage, data consultancy, and software services [5].